To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
deCODE and UCB Announce Discovery and Development Collaboration for Anti-Inflammatory Drugs
Read time: Less than a minute
deCODE chemistry & biostructures
has announced the initiation of a collaboration with
UCB
. Under the terms of the deal, deCODE and UCB will collaborate on the structure-based discovery of small molecule modulators of undisclosed cytokine targets.
The program will focus on integrated structure-based drug design leveraging deCODE’s Fragments of Life™ technology for lead identification and optimization. As the program advances, it may also capitalize on deCODE's expertise in ADMET and PK/PD. The financial terms of the research fee, milestone and royalty-bearing relationship were not disclosed.
The program will focus on integrated structure-based drug design leveraging deCODE’s Fragments of Life™ technology for lead identification and optimization. As the program advances, it may also capitalize on deCODE's expertise in ADMET and PK/PD. The financial terms of the research fee, milestone and royalty-bearing relationship were not disclosed.
